Author Correction: BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer (Scientific Reports, (2015), 5, 1, (17499), 10.1038/srep17499)

Niki Karachaliou, Jordi Codony-Servat, Cristina Teixidó, Sara Pilotto, Ana Drozdowskyj, Carles Codony-Servat, Ana Giménez-Capitán, Miguel Angel Molina-Vila, Jordi Bertrán-Alamillo, Radj Gervais, Bartomeu Massuti, Teresa Morán, Margarita Majem, Enriqueta Felip, Enric Carcereny, Rosario García-Campelo, Santiago Viteri, María González-Cao, Daniela Morales-Espinosa, Alberto VerlicchiElisabetta Crisetti, Imane Chaib, Mariacarmela Santarpia, José Luis Ramírez, Joaquim Bosch-Barrera, Andrés Felipe Cardona, Filippo de Marinis, Guillermo López-Vivanco, José Miguel Sánchez, Alain Vergnenegre, José Javier Sánchez Hernández, Isabella Sperduti, Emilio Bria, Rafael Rosell*

*Corresponding author for this work

Research output: Contribution to journalArticleResearchpeer-review

1 Citation (Scopus)

Abstract

This Article contains an error in Figure 3A, where the mTOR panel is an inadvertent duplication of the BIM panel. The corrected Figure 3 and accompanying legend appear below. In addition, the Supplementary Information file published with this Article contains an error in Supplementary Figure 3A, where the mTOR panel is inadvertently duplicated from the BIM panel. The corrected Supplementary Information file is provided below.

Original languageEnglish
Article number3620
Number of pages2
JournalSCIENTIFIC REPORTS
Volume13
Issue number1
DOIs
Publication statusPublished - Dec 2023

Fingerprint

Dive into the research topics of 'Author Correction: BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer (Scientific Reports, (2015), 5, 1, (17499), 10.1038/srep17499)'. Together they form a unique fingerprint.

Cite this